Home » Newsletters » BioWorld Science

BioWorld Science

July 1, 2019

View Archived Issues

IDEAYA Biosciences initiates phase I/II study of IDE-196

A novel androgen receptor antagonist is a promising candidate for enzalutamide-resistant CRPC

BR-11257, a novel nonstabilizing soluble guanylyl cyclase partial agonist

AptaTargets initiates first-in-human trial of ApTOLL

Bayer initiates phase II AVANTI study of BAY-1753011 in congestive heart failure

ImmusanT discontinues phase II study of Nexvax2 in celiac disease

MolMed suspends enrollment of new patients in phase III TK008 study of Zalmoxis

Phase II results presented for pazopanib in patients with progressive carcinoid tumors

Notch1 as a promising new therapeutic target in multiple myeloma

[18F]Afatinib PET/CT as promising new tool for selecting patients with NSCLC for afatinib therapy

Addressing glioblastoma by targeting LDLR with VH-DO-33 radioisotopes

Amino acid derivative may be schizophrenia treatment

Cryptic sensitivity can be unmasked in MRSA

EBV's metabolic transformation

Enanta Pharmaceuticals patents anti-HBV agents

Rockefeller University presents kappa-opioid receptor agonists

GlaxoSmithKline identifies mTOR inhibitors

Roche describes MGL inhibitors

Leo Pharma divulges PDE4 and TNF-alpha release inhibitors

Identification of atrovimycin, a novel antitubercular and antifungal cyclodepsipeptide

ADC Therapeutics presents phase I data for loncastuximab tesirine in R/R DLBCL

Guerbet begins phase III study of contrast agent gadopiclenol for CNS imaging

Vedanta's live biotherapeutic product candidate VE-416 begins phase Ib/II study for peanut allergy

Phase III study of sildenafil in newborns with PPHN does not meet primary efficacy endpoint

Oxurion reports phase I topline data on THR-149 in DME

Danish Medicines Agency approves AJ Vaccines' polio vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
Janssen Pharmaceutica reports new TMEM175 activators
BioWorld Science
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...
Cancer specter looming, Abtect effect in UC wallops Abivax
BioWorld
Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...